AZD3839 - CAS 1227163-56-5
Catalog number: 1227163-56-5
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C24H15F4N5
Molecular Weight:
449.40
COA:
Inquire
Targets:
β-secretase
Description:
AZD3839, with the potential to treat Alzheimer’s disease, was reported as a selective BACE1 inhibitor (IC50=4.8μM) for which concentration-dependent lowering of Ab peptides in cellular systems and three pre-clinical species were demonstrated. Phase-I for Alzheimer's disease in United Kingdom (PO) was discontinued in 2012 in UK.
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Appearance:
Solid powder
Synonyms:
4-Fluoro-1-[3-(5-pyrimidinyl)phenyl]-1-[2-(trifluoromethyl)-4-pyridinyl]-1H-isoindol-3-amine; AZD-3839; AZD 3839;(3S)-3-(2-(difluoromethyl)pyridin-4-yl)-7-fluoro-3-(3-(pyrimidin-5-yl)phenyl)isoindolin-1-amine
Solubility:
Soluble in DMSO, not in water
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
Alzheimer's disease
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
Density:
1.43±0.1 g/cm3
InChIKey:
QXKYWSDUVAJHNZ-CGAIIQECSA-N
InChI:
InChI=1S/C24H18F3N5/c25-19-6-2-5-18-21(19)23(28)32-24(18,17-7-8-31-20(10-17)22(26)27)16-4-1-3-14(9-16)15-11-29-13-30-12-15/h1-13,22-23,32H,28H2/t23?,24-/m0/s1
Canonical SMILES:
C1=CC(=CC(=C1)C2(C3=C(C(N2)N)C(=CC=C3)F)C4=CC(=NC=C4)C(F)F)C5=CN=CN=C5
Current Developer:
AstraZeneca
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related β-secretase Products


CAS 989-51-5 EGCG

EGCG
(CAS: 989-51-5)

EGCG, also called Epigallocatechin gallate, under the IUPAC name [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxy...

CAS 1254166-60-3 Imidazo[1,2-a]pyridine-2-carboxamide, 6-chloro-N-[6-(phenylmethoxy)-1H-benzimidazol-2-yl]-

Imidazo[1,2-a]pyridine-2-carboxamide, 6-
(CAS: 1254166-60-3)

An inhibitor of β-site amyloid precursor protein-cleaving enzyme (BACE)

AMG-8718
(CAS: 1215868-94-2)

This active molecular is a potent BACE1 inhibitor that is a potential target for the treatment of Alzheimer's disease. AMG-8718 produced significantly reduction...

CAS 1383982-64-6 Lanabecestat

Lanabecestat
(CAS: 1383982-64-6)

Lanabecestat, also referred to AZD3293,is an orally active and highly permeable potent inhibitor of human β-secretase 1 in clinical development for the treatmen...

CAS 1262036-50-9 LY2886721

LY2886721
(CAS: 1262036-50-9)

LY2886721, under the IUPAC name N-(3-(2-amino-4a,5,7,7a-tetrahydro-4H-furo(3,4-d)(1,3)thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide, is the first oral sma...

Verubecestat
(CAS: 1286770-55-5)

Verubecestat, a iminothiadiazine dioxide compound, is an oral BACE1 inhibitor originated by Merck & Co. It can bind significantly to β-secretase. Verubecestat h...

AZD3293
(CAS: 1628076-74-3)

AZD3293, a spiro compound, has been found to be a β-secretase inhibitor that has good blood-brain barrier penetration and could probably be significant in studi...

CAS 797035-11-1 BACE-1 Inhibitor

BACE-1 Inhibitor
(CAS: 797035-11-1)

BACE-1 Inhibitor is a potent, selective and cell-permeable inhibitor of human β-secretase (BACE-1) binding to the active site of BACE-1. It inhibits secretion o...

PF-05297909

PF-05297909, is a BACE inhibitor developed by Pfizer. Phase 1

E2609

E2609, developed by Eisai Inc, is a novel, small molecule, BACE1 inhibitor that has been shown in nonclinical studies to inhibit the production of Aβ40 and Aβ42...

AZD3839
(CAS: 1227163-56-5)

AZD3839, with the potential to treat Alzheimer’s disease, was reported as a selective BACE1 inhibitor (IC50=4.8μM) for which concentration-dependent lowering of...

VTP-37948

VTP-37948, also called BI 1181181, being clinically developed with Boehringer Ingelheim and Vitae Pharmaceuticals, is a is an inhibitor targeted to the catalyti...

AZD3839
(CAS: 1227163-84-9)

AZD3839, also called CHEMBL2177913, as a a potent BACE1 inhibitor it is a clinical candidate for the treatment of Alzheimer's disease. Studies indicate that the...

HPP854

HPP854, developed by High Point Pharmaceuticals, is a small molecule BACE1 protein inhibitor. Phase 1

CAS 1262036-49-6 LY 2886721 hydrochloride

LY 2886721 hydrochloride
(CAS: 1262036-49-6)

LY 2886721 hydrochloride is the first oral inhibitor of human β-secretase (BACE-1) with the potential to treat Alzheimer's Disease.

TAK-070
(CAS: 365276-12-6)

TAK-070, under the IUPAC name 2-​Naphthaleneethanamin​e, 6-​([1,​1'-​biphenyl]​-​4-​ylmethoxy)​-​1,​2,​3,​4-​tetrahydro-​N,​N-​dimethyl-​, hydrochloride, hydrat...

CAS 244081-42-3 Rafabegron

Rafabegron
(CAS: 244081-42-3)

Rafabegron is a potent and selective beta3-adrenoceptor agonist.

RG7129
(CAS: 1628077-06-4)

RG7129, developed by Roche, inhibit BACE to treat Alzheimer's disease. Phase-I

CTS-21166

CTS-21166, the selective BACE1 inhibitor whose structure is not revealed, reduce brain Aβ levels by over 35% and plaque load by 40%. Phase 1 IC50=1.2–3.6 nM (ce...

CAS 1194044-20-6 LY2811376

LY2811376
(CAS: 1194044-20-6)

LY2811376, under the IUPAC name (4S)-4-(2,4-difluoro-5-pyrimidin-5-ylphenyl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine, is the first orally available non-peptidi...

Quick Inquiry

Verification code

Featured Items